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For government construction projects, 
“shovel readiness” means managers are 
ready to hire shovel-wielding workers as 
soon as the money becomes available. 
But when the US Congress passed 
the stimulus package—more formally 
known as the American Recovery and 
Reinvestment Act (ARRA)—in Febru-
ary last year, the National Institutes of 
Health (NIH) needed to figure out how 
to translate this concept into research 
projects carried out by pipette-wielding 
scientists.
A year ago, NIH officials were con-
fronted with the task of distributing 
a huge stimulus bounty of $8.2 billion 
for research projects and $1.8 million 
for construction and equipment. These 
funds were in addition to the regular 
$30.3 billion allocated to the NIH in 
2009. “We were overjoyed at being able 
to participate,” says Sally Rockey, NIH’s 
acting deputy director for extramural 
research. “We knew that research uni-
versities play a powerful role in driving 
the economic engine in many commu-
nities.” Although not explicitly targeting 
job creation, the NIH resolved to choose 
from among the flood of applications 
(30,000 in the 2009 fiscal year) high-
quality research projects with the ability 
to produce results quickly, while fac-
toring in geographic balance. Looming 
over these decisions was the require-
ment that stimulus money be spent in 
2 years, and the expectation that Con-
gress would not be as generous with the 
NIH in future years. One year later, with 
most of the money committed, a com-
plex picture is emerging of how these 
factors are playing out.
Where Did the Money Go?
The NIH institutes allocated a grand total 
of $4.8 billion in ARRA funds in 2009 but 
did so in different ways (http://report.
nih.gov/UploadDocs/Final_NIH_ARRA_
FY2009_Funding.pdf; Table 1). For 
example, some institutes favored pay-
line extensions. These fit into the existing 
peer review framework for traditional NIH 
grants, enabling the funding of projects 
that narrowly missed being supported in 
2008 and 2009. Meanwhile, other insti-
tutes favored administrative supplements, 
which offered speed (principal investiga-
tors applied directly to NIH program offi-
cers) and the ability to keep postdocs 
or technicians on the job or upgrade old 
equipment. In addition, ARRA-specific 
programs such as the Challenge and 
Grand Opportunity grants were designed 
to drive one-time investment into spe-
cific research areas such as biomarkers, 
genomics, and regenerative medicine 
and could reward fresh ideas, with appli-
cations not requiring as much preliminary 
data. Another ARRA-specific program, 
p30 core center grants, bolstered recruit-
ment packages for new faculty hires.
The National Institute of General Medi-
cal Sciences (NIGMS) devoted the larg-
est portion of its $505 million stimulus 
allocation over 2 years to administrative 
supplements. “We ended up funding 
more administrative supplements than we 
expected initially,” says director Jeremy 
Berg. “We felt this made sense because 
we tend to cut individual projects’ budgets 
more aggressively than other institutes, 
and because it seemed to fit the Recovery 
Act’s aims of getting money to people who 
can hit the ground running.” Meanwhile, 
the National Cancer Institute (NCI) spent a 
A Grand Experiment  
in Shovel-Ready Science
The 2009 stimulus package released a burst of pent-up creativity in the applications submitted 
by US researchers, but there was a complicating factor with funding decisions: the need for quick 
results. Quinn Eastman provides a progress report.
Table 1. NIH ARRA-Funded Allocations in 2009a
NIH ARRA Funding for FY2009 Amount # of Awards Average Size
Grants $4.35 billion 
(12,786 projects)
R&D contracts $390 million
Intramural support + administration $80 million
Total $4.82 billion
Breakdown of Grants
New ARRA-specific programs $1.15 billion 1436 $801,000
Payline extension $1.43 billion 3894 $367,000
Competing supplements $220 million 419 $520,000
Administrative supplements $1.51 billion 5687 $265,000
Summer supplements $45 million 1350 $33,000
Breakdown of New ARRA-Specific Programsb
Minority health and health disparities $6.4 million 17
Heterogeneity in autism spectrum disorders $35.3 million 60
Challenge grants $389 million 840
Grand opportunities $625 million 376
P30 core center grants $80.5 million 141
Networking resources $13.5 million 2
aEstimated job creation/retention: 50,000 people.
bSome ARRA-specific programs, such as translational grants to small businesses, did not begin 
until fiscal year 2010.
Source: http://report.nih.gov/UploadDocs/Final_NIH_ARRA_FY2009_Funding.pdf
sizable fraction of its stimulus money ($318 
million out of a $1.26 billion 2 year ARRA 
allocation) on competitive contracts, such 
as high-throughput sequencing for the 
Cancer Genome Atlas project.
Other institutes, such as the National 
Institute of Allergy and Infectious Dis-
eases (NIAID) and the National Institute 
of Neurological Disorders and Stroke 
(NINDS), directed the largest portion of 
their ARRA money ($1.12 billion and $400 
million, respectively) toward increasing 
the number of individual research grants 
funded. “We had so much good science 
that was already reviewed and scored,” 
says NIAID director Tony Fauci. “It made 
sense to distribute our ARRA money to as 
many investigators as possible.” NINDS 
director Story Landis concurs. “Because 
paylines have been so low, we had an 
extraordinary number of outstanding 
grants that were not funded,” she says. “In 
most cases, these were already scored in 
peer review and were ready to go.”
Research deans and lucky recipients of 
stimulus money say that the diverse array 
of opportunities provided flexibility. As 
chair of the University of California, San 
Diego’s section of neurobiology, Anirvan 
Ghosh used ARRA funds to recruit two 
new faculty members for UCSD’s Cen-
ter for Neural Circuits and Behavior. Part 
of their startup packages came from a 
p30 core center grant from NINDS and 
the National Institute of Mental Health 
(NIMH). “Increasing demand for top-level 
instrumentation means assembling com-
petitive startup packages in neuroscience 
is difficult,” Ghosh says. “This funding 
mechanism greatly facilitated that task, 
especially when we had a university-wide 
hiring freeze.” For his own laboratory, 
Ghosh also won an ARRA-funded Chal-
lenge grant to systematically create a 
large number of “knock-in” mouse lines, 
each of which can be used to probe the 
function of a specific class of neurons.
A broad illustration of the impact of 
ARRA funds disbursed through payline 
extensions comes from the University 
of Pennsylvania. “We had a problem 
where established investigators, for the 
first time, were not getting their grants 
renewed, and about 40 of them were 
looking at laying off postdocs or tech-
nical staff,” reports Penn’s vice provost 
for research Steve Fluharty. University 
administrators were willing to provide 
bridge funding for 2 years, but the ARRA-
funded payline extensions restored sup-
port to the majority of this group.
Through ARRA administrative supple-
ments from NIGMS, Mark Peifer, a cell 
biologist at the University of North Caro-
lina, kept two senior postdocs in the 
laboratory for an extra year. He also was 
able to spruce up a confocal microscope 
critical for their work on Wnt signal-
ing and cell adhesion. “For us, this has 
been terrific,” he says. “Over the course 
of the year, we were able to do some 
great experiments and are now sending 
out two manuscripts. And the souped-
up microscope is something everyone in 
our department can use.”
Predicting Where Progress Will 
Come?
But how did NIH officials and scientists 
together determine whether projects 
were “shovel-ready”? One obvious inter-
pretation of this prerequisite for stimulus 
funds is that projects should involve the 
construction of new buildings or buying 
new equipment. For example, the NIH’s 
National Center for Research Resources 
(NCRR) distributed $10.4 million (14 
grants) of ARRA funds for electron 
microscopes or related infrastructure 
and $24.2 million (46 grants) for confocal 
microscopes in 2009 and 2010.
NIH officials also pledged to fund the 
research projects that would have the 
best chance of making scientific progress 
in the limited 2 year timeframe—difficult 
under any circumstances. Examining the 
abstracts of Challenge grants reveals 
that some investigators took advantage 
of having samples already collected. 
Lest that imply lack of imagination, the 
“in the freezer already” aspect was usu-
ally combined with a new technique or 
technology. For example, at the Univer-
sity of Michigan, Vince Young, a microbi-
ologist using next-generation sequencing 
techniques, is collaborating with John 
LiPuma, a clinician with a treasure trove 
of thousands of patient sputum samples. 
The project—analyzing the microbes that 
colonize the lungs of patients with cystic 
fibrosis—is funded by a Challenge grant 
from the National Heart, Lung and Blood 
Institute (NHLBI). “We had been talking 
about teaming up, but didn’t have a lot of 
preliminary data,” Young says. “This was 
a great way to jump start the project.”
Genome sequencing technology, 
another common theme for many stimulus 
projects, is driving advances such as Jim 
Lupski’s research on Charcot-Marie-Tooth 
disease, from which he suffers. Lupski, 
based at the Baylor College of Medicine, 
recently identified new mutations causing 
Charcot-Marie-Tooth disease by sequenc-
ing his own entire genome and sections 
of the genomes of his parents and sib-
lings. He received stimulus money from 
NINDS to continue his work on genomic 
rearrangements and neurological dis-
ease. “This was a wonderful example of 
how whole genome analysis could inform 
the diagnosis and potentially the care of 
patients with a variety of disorders,” says 
NINDS director Landis.
Beyond physical equipment, several 
stimulus-funded projects involve creat-
ing resources that the entire scientific 
community can use, long after the money 
expires. Examples include the Ameri-
can Society of Cell Biology’s assembly 
of microscope slide images into a vast 
searchable database, and Ghosh’s Chal-
lenge grant project that is creating many 
knock-in mouse lines.
Regarding clinical trials, which often 
take several years to complete, not all 
institutes handled them the same way. 
Using stimulus money, NCI funded 37 
early-phase trials under the ACTNOW 
(Accelerating Clinical Trials of Novel 
Oncologic PathWays) program. In con-
trast, NIAID steered away from using 
stimulus money for clinical trials, reports 
director Fauci. “The timeframe wasn’t 
right for most [clinical trial] proposals 
we looked at,” he says. “We were able to 
accelerate a few exciting projects related 
to HIV treatment and prevention, and 
also pandemic flu. This allowed them to 
get rolling in 2009 instead of 2010.”
Spreading the Wealth
The issue of geographic balance when 
handing out NIH funds has rumbled in 
Congress for years, says David Gold-
ston, former staff director for the House 
Committee on Science. “This has been 
a chronic issue, but less than at other 
federal research agencies, because 
research on health can reasonably 
claim to benefit the entire country,” he 
says. “So far, the struggle has been over 
which diseases to focus on, rather than 
geography.”182 Cell 142, July 23, 2010 ©2010 Elsevier Inc.
However, the topic came to the forefront 
in May when NIH director Francis Col-
lins laid out the 2011 NIH budget request 
for the Senate Appropriations Commit-
tee. Senator Thad Cochran (R-MS) cited 
the Jackson Heart Study, a decade-long 
examination of cardiovascular disease in 
African Americans, to show that states 
not usually thought of as research power-
houses can make important contributions. 
He then asked for further review, so that 
“some states are not treated too much 
better than everybody else.” At the hear-
ing, Collins pointed out that construction, 
funded by the NIH’s NCRR, has helped to 
ensure that stimulus spending was spread 
more evenly across the US. Twenty-three 
US states (including Mississippi) are eli-
gible for NCRR Institutional Development 
Awards (IdEA) based on low success rates 
when applying for NIH grants. IdEA states 
received 18% of NCRR’s $1.6 billion in 
stimulus money; overall, IdEA states gar-
nered 9% of ARRA funds, compared with 
just 7% of the regular NIH budget.
Some non-IdEA states, like Florida, 
markedly increased their share of NIH 
money thanks to generous stimulus fund-
ing. Florida’s ARRA haul—39% of its share 
of the regular 2009 NIH budget—was due 
to awards to the University of Florida to 
launch the largest ever clinical study for 
preventing mobility disability in seniors 
($11 million) and to expand “VIVO,” a social 
network for biomedical researchers ($6 
million), in addition to a construction grant 
for its center for aging research.
Keep the Pipeline Flowing
Younger scientists applying for their first 
NIH grant now get an advantage relative 
to their more established colleagues, 
thanks to policies that NIH’s director 
from 2002 to 2008, Elias Zerhouni, first 
experimented with and then formal-
ized. These measures are intended to 
“keep the pipeline flowing” and pre-
vent early stage scientists’ applications 
from being overshadowed by those with 
more experience, says Sally Rockey at 
NIH. The gap in success rates between 
first-time applicants and established 
investigators for new (non-renewal) 
R01-equivalent grants was closed for 
the first time in 2009 (http://report.nih.
gov/nihdatabook /Char ts/SlideGen.
aspx?chartId=136&catId=13).
However, these data do not include 
awards made under ARRA, and what 
success rates would look like after fac-
toring them in is a complicated question, 
Rockey says.
When it came to stimulus money, NIH 
officials did not make special provi-
sions for newer investigators, and fund-
ing mechanisms such as administrative 
supplements tended to favor established 
scientists.
In addition, several institutes, such as 
NIGMS, NIAID, and NINDS, advised early 
stage investigators who hadn’t obtained 
5 year R01 grants not to apply for 2 year 
ARRA funds because they would lose 
the advantage of early stage status and 
would have to apply again quickly. “We 
didn’t want them to get caught in a bind,” 
says NIAID director Fauci. He says that 
ARRA provided indirect benefits to newer 
scientists. NIAID’s 5 year R01 payline for 
new investigators jumped from 14% in 
2008 to 25% in 2009, whereas the pay-
line for experienced investigators stayed 
at 12%. (The spread for 2010 isn’t as 
much: 16% versus 11%.)
Other institutes, such as NCI and 
NHLBI, funded some newer investiga-
tors with ARRA money but committed 
to supporting them after 2 years with 
money from the regular budget. This 
commitment was intended to mitigate 
the impact of possibly flat budgets in 
coming years, according to NCI officials. 
Under federal rules, cost-free extension 
of 2 year grants to 3 years is seen as rel-
atively routine, but anything beyond that 
would require special permission.
“Even though no special provisions 
were made for early-stage investigators, 
they did quite well,” Rockey says, not-
ing that more than 2000 investigators 
obtained grants for the first time through 
the stimulus. The stimulus also enabled 
a surge in the number of New Innovator 
awards—part of the NIH Roadmap pro-
gram designed to promote transformative 
research and limited to early-stage inves-
tigators—from 31 recipients in 2008 to 55 
in 2009. The stimulus program that has 
most benefitted postdoctoral research-
ers making a transition to independence 
is the p30 core center grant, says Stacy 
Gelhaus, a cancer pharmacologist and 
chair of the National Postdoctoral Asso-
ciation’s board of directors. She points 
out that stimulus money did not increase 
the number of “F” postdoctoral fellow-
ships or “K” mentored career develop-
ment awards, although some adminis-
trative supplements for these types of 
awards were made available. The p30 
program was the response of NIH offi-
cials to the tight state budgets and dimin-
ished endowments of universities across 
the country that were delaying or cancel-
ing the hiring of new faculty, says NIGMS 
director Berg. Because of low paylines 
and success rates, junior faculty have 
been relying on startup funds for longer 
periods, he says. Out of several ARRA-
specific funding programs, Berg identi-
fied the p30 program as one he’d like to 
see continue. “The benefits we’ve seen 
have to be weighed against entry into uni-
versities’ capacity decisions and increas-
ing future demand for grants,” he says.
As part of a new federal initiative (STAR 
METRICS), economists are beginning to 
develop metrics to evaluate the impact 
of the stimulus package on both the sci-
entific landscape and the research work-
force. “It looks like it was good to be a 
new investigator in the last two years,” 
says Richard Freeman, a labor econo-
mist at Harvard who is planning to sur-
vey university officials and researchers 
on how they used stimulus funds. “A few 
years down the road, incoming people 
will be competing against the current 
group, which got a bit of an edge.”
Freeman described the stimulus pack-
age as a societal experiment for gaug-
ing the effects of a pulse of funding on 
research. As scientists and NIH officials 
recover from the roller-coaster ride of 
applying for and receiving ARRA money 
last year, they may be pondering whether 
policymakers will take a more results- 
and metrics-oriented approach to evalu-
ating the success of government-funded 
research in the future. If so, the achieve-
ments coming out of the 2 year stimulus 
experiment will be of intense interest.
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